Estimation of VLDL, IDL, LDL, HDL2, apoA-I, and apoB from the Friedewald inputsapoB and IDL, but not LDL, are associated with mortality in type 1 diabetes

Annals of Medicine

Volumn 41, Issue 6, 2009, Pages 451-461

  Niemi, Jaakko ^a   Mäkinen, Ville Petteri ^a,b,c   Heikkonen, Jukka ^a   Tenkanen, Leena ^d   Hiltunen, Yrjö ^e   Hannuksela, Minna L ^f   Jauhiainen, Matti ^g   Forsblom, Carol ^b,c   Taskinen, Marja Riitta ^h   Kesäniemi, Y Antero ^f   Savolainen, Markku J ^f   Kaski, Kimmo ^a   Groop, Per Henrik ^b,c   Kovanen, Petri T ⁱ   Ala Korpela, Mika ^a,b,c  

^a AALTO UNIVERSITY   (Finland)

^b Folkhlsan Research Center   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Helsinki Heart Study ^*  (Finland)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY OF OULU   (Finland)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Diabetes mellitus; Lipid metabolism; Medical informatics computing; Metabolic diseases; Neural networks (computer); Ultracentrifugation; Vascular diseases

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN 2; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COST; CROSS-SECTIONAL STUDY; DEATH; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL MODEL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

ALGORITHMS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS; MODELS, STATISTICAL; REGRESSION ANALYSIS; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 70350489596     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890902893392     Document Type: Article

References (41)

1. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109:2-7
2. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, et al. Beyond low-density lipoprotein cholesterol. J Am Coll Cardiol. 2007;50:1735-1741
3. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502
4. Warnick GR, Myers GL, Cooper GR, Rifai N. Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. Clin Chem. 2002;48:11-17
5. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033
6. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375-3383 (Pubitemid 43739551)
7. St-Pierre A, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men. 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553-559 (Pubitemid 40315677)
8. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008; 372:224-233
9. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002;106:2137-2142
10. Hodis HN, Mack WJ, Dunn M, Liu CR, Liu CH, Selzer RH, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95:2022-2026
11. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770
12. Majeed F, Miller M. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. Curr Opin Endocrinol Diabetes Obes. 2008; 2:175-181
13. Bruckert E, Hansel B. HDL-C is a powerful lipid predictor of cardiovascular diseases. Int J Clin Pract. 2007;11:1905-1913
14. Morgan J, Carey C, Lincoff A, Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep. 2004;6:359-365
15. Savolainen MJ, Rantala M, Kervinen K, Jarvi L, Suvanto K, Rantala T, et al. Magnitude of dietary effects on plasma cholesterol concentration: role of sex and apolipoprotein E phenotype. Atherosclerosis. 1991;86:145-152
16. Hannuksela M, Marcel YL, Kesaniemi YA, Savolainen MJ. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res. 1992;33:737-744
17. Savolainen MJ, Korhonen T, Aalto-Setala K, Kontula K, Kesaniemi YA. Screening for a prevalent LDL receptor mutation in patients with severe hypercholestrolaemia. Hum Genet. 1991;87:125-128
18. Horkko S, Huttunen K, Korhonen T, Kesaniemi YA. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. Kidney Int. 1994;45:561-570 (Pubitemid 24065094)
19. Ala-Korpela M, Korhonen A, Keisala J, Horkko S, Korpi P, Ingman LP, et al. 1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. J Lipid Res. 1994;35:2292-2304
20. Makinen VP, Forsblom C, Thorn L, Waden J, Gordin D, Heikkila O, et al. FinnDiane Study Group. Metabolic phenotypes, vascular complications and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes. 2008;57:2480-2487
21. Siggins S, Jauhiainen M, Olkkonen VM, Tenhunen J, Ehnholm C. PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma. J Lipid Res. 2003;44:1698-1704
22. Baxt WG. Application of artificial neural networks to clinical medicine. Lancet. 1995;346:1135-1138
23. Vaänanen T, Koskela H, Hiltunen Y, Ala-Korpela M. Application of quantitative artificial neural network analysis to 2D NMR spectra of hydrocarbon mixtures. J Chem Inf Comput Sci. 2002;42:1343-1346
24. Bishop CM. Neural networks for pattern recognition. New York: Oxford University Press, 1995
25. Tolonen N, Forsblom C, Thorn L, Waden J, Rosengard-Barlund M, Saraheimo M, et al. Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia. 2008;51:12-20
26. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310
27. Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;34:187-220
28. Gazi I, Tsimihodimos V, Filippatos TD, Saougos VG, Bairaktari ET, Tselepis AD, et al. LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis. 2006;5:8
29. Planella T, Cortes M, Martinez-Bru C, Gonzalez-Sastre F, Ordonez-Llanos J. Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipidemia. Clin Chem. 1999;43:808-815
30. Wagner AM, Zapico E, Bonet R, Perez A, Ordonez-Llanos J. The effect of VLDL particles on the accuracy of a direct LDL-cholesterol method in type 2 diabetic patients. Clin Biochem. 2003;36:177-183
31. Ran Jun K, Park HI, Chun S, Park H, Min WK. Effects of total cholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula. Clin Chem Lab Med. 2008;46:371-375
32. Tighe DA, Ockene IS, Reed G, Nicolosi R. Calculated low density lipoprotein cholesterol levels frequently underestimate directly measured low density lipoprotein cholesterol determinations in patients with plasma triglyceride levels 54.52 mmol/l: an analysis comparing the LipiDirect magnetic LDL assay with the Friedewald calculation. Clin Chim Acta. 2006;365:236-242
33. McFarlane C, Young IS, Hare L, Mahon G, McEneny J. A rapid methodology for the isolation of intermediate-density lipoprotein: characterization of lipid composition and apoprotein content. Clin Chim Acta. 2005;353:117-125
34. Libby P, Nathan D, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group of Cardiovascular Complications of type 1 diabetes mellitus. Circulation. 2005;111:3489-3493
35. Pambianco G, Costacou T, Orchard T The prediction of major outcomes of type 1 diabetes: a 12 year prospective evaluation of three separate definitions of the metabolic syndrome, and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care. 2007;30: 1248-1254
36. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hooqwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426
37. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis. 1997;131: 229-236
38. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol. 1998;9:1277-1284
39. Makinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, Kaski K, et al. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol. 2008;4:167
40. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the Thirty-Person/Ten-Country Panel. J Intern Med. 2006;259:247-258
41. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev. 2007;65:152-156